Logo image of GLPG.AS

GALAPAGOS NV (GLPG.AS) Stock Fundamental Analysis

Europe - AMS:GLPG - BE0003818359 - Common Stock

27.9 EUR
-0.24 (-0.85%)
Last: 9/25/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to GLPG. GLPG was compared to 77 industry peers in the Biotechnology industry. While GLPG seems to be doing ok healthwise, there are quite some concerns on its profitability. GLPG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

GLPG had negative earnings in the past year.
GLPG had a negative operating cash flow in the past year.
In multiple years GLPG reported negative net income over the last 5 years.
GLPG had a negative operating cash flow in each of the past 5 years.
GLPG.AS Yearly Net Income VS EBIT VS OCF VS FCFGLPG.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

1.2 Ratios

GLPG has a Return On Assets of -7.45%. This is in the better half of the industry: GLPG outperforms 63.64% of its industry peers.
The Return On Equity of GLPG (-10.75%) is better than 70.13% of its industry peers.
Industry RankSector Rank
ROA -7.45%
ROE -10.75%
ROIC N/A
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
GLPG.AS Yearly ROA, ROE, ROICGLPG.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

GLPG's Profit Margin has improved in the last couple of years.
With an excellent Gross Margin value of 87.59%, GLPG belongs to the best of the industry, outperforming 80.52% of the companies in the same industry.
In the last couple of years the Gross Margin of GLPG has declined.
The Profit Margin and Operating Margin are not available for GLPG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
GLPG.AS Yearly Profit, Operating, Gross MarginsGLPG.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

More info and screens

5

2. Health

2.1 Basic Checks

GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GLPG has about the same amount of shares outstanding.
Compared to 5 years ago, GLPG has more shares outstanding
GLPG has a worse debt/assets ratio than last year.
GLPG.AS Yearly Shares OutstandingGLPG.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLPG.AS Yearly Total Debt VS Total AssetsGLPG.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

GLPG has an Altman-Z score of 1.49. This is a bad value and indicates that GLPG is not financially healthy and even has some risk of bankruptcy.
GLPG's Altman-Z score of 1.49 is fine compared to the rest of the industry. GLPG outperforms 62.34% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that GLPG is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, GLPG belongs to the top of the industry, outperforming 88.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.49
ROIC/WACCN/A
WACC7.85%
GLPG.AS Yearly LT Debt VS Equity VS FCFGLPG.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

A Current Ratio of 8.08 indicates that GLPG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.08, GLPG belongs to the top of the industry, outperforming 89.61% of the companies in the same industry.
A Quick Ratio of 7.99 indicates that GLPG has no problem at all paying its short term obligations.
GLPG has a Quick ratio of 7.99. This is amongst the best in the industry. GLPG outperforms 89.61% of its industry peers.
Industry RankSector Rank
Current Ratio 8.08
Quick Ratio 7.99
GLPG.AS Yearly Current Assets VS Current LiabilitesGLPG.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

The earnings per share for GLPG have decreased strongly by -200.70% in the last year.
The earnings per share for GLPG have been decreasing by -12.47% on average. This is quite bad
The Revenue for GLPG has decreased by -52.50% in the past year. This is quite bad
The Revenue for GLPG have been decreasing by -20.82% on average. This is quite bad
EPS 1Y (TTM)-200.7%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-1242.86%
Revenue 1Y (TTM)-52.5%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%-16.16%

3.2 Future

The Earnings Per Share is expected to decrease by -40.64% on average over the next years. This is quite bad
GLPG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.04% yearly.
EPS Next Y-346.2%
EPS Next 2Y-85.58%
EPS Next 3Y-65.78%
EPS Next 5Y-40.64%
Revenue Next Year-5.39%
Revenue Next 2Y-4.01%
Revenue Next 3Y-4.07%
Revenue Next 5Y0.04%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GLPG.AS Yearly Revenue VS EstimatesGLPG.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
GLPG.AS Yearly EPS VS EstimatesGLPG.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLPG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLPG.AS Price Earnings VS Forward Price EarningsGLPG.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLPG.AS Per share dataGLPG.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

A cheap valuation may be justified as GLPG's earnings are expected to decrease with -65.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-85.58%
EPS Next 3Y-65.78%

More info and screens

0

5. Dividend

5.1 Amount

GLPG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALAPAGOS NV

AMS:GLPG (9/25/2025, 7:00:00 PM)

27.9

-0.24 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-23 2025-07-23/amc
Earnings (Next)10-22 2025-10-22
Inst Owners49.75%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.84B
Analysts48.24
Price Target29.5 (5.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1378.49%
Min EPS beat(2)-1682.53%
Max EPS beat(2)-1074.45%
EPS beat(4)1
Avg EPS beat(4)-663.96%
Min EPS beat(4)-1682.53%
Max EPS beat(4)154.1%
EPS beat(8)5
Avg EPS beat(8)-142.38%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.96%
Min Revenue beat(2)-10.27%
Max Revenue beat(2)4.35%
Revenue beat(4)1
Avg Revenue beat(4)-8.31%
Min Revenue beat(4)-15.5%
Max Revenue beat(4)4.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.14%
PT rev (3m)-2.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-150.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.23%
Revenue NY rev (3m)0.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.67
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-4.32
EYN/A
EPS(NY)-1.62
Fwd EYN/A
FCF(TTM)-4.52
FCFYN/A
OCF(TTM)-4.23
OCFYN/A
SpS4.18
BVpS40.12
TBVpS36.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.45%
ROE -10.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.59%
FCFM N/A
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.7%
GM growth 3Y-4.31%
GM growth 5YN/A
F-Score1
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.4%
Cap/Sales 7.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.08
Quick Ratio 7.99
Altman-Z 1.49
F-Score1
WACC7.85%
ROIC/WACCN/A
Cap/Depr(3y)93.66%
Cap/Depr(5y)187.37%
Cap/Sales(3y)17.05%
Cap/Sales(5y)15.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-200.7%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-1242.86%
EPS Next Y-346.2%
EPS Next 2Y-85.58%
EPS Next 3Y-65.78%
EPS Next 5Y-40.64%
Revenue 1Y (TTM)-52.5%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%-16.16%
Revenue Next Year-5.39%
Revenue Next 2Y-4.01%
Revenue Next 3Y-4.07%
Revenue Next 5Y0.04%
EBIT growth 1Y-98.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.31%
EBIT Next 3Y-19.94%
EBIT Next 5Y14.76%
FCF growth 1Y45.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.13%
OCF growth 3YN/A
OCF growth 5YN/A